ASTRAZENECA PLC vs ELI LILLY & Co, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where AZN and LLY diverge most: on debt / equity, AZN reads 0.00 and LLY reads 1.39; on ev/ebitda, AZN reads 18.6 and LLY reads 2180.2. The rest of the comparable metrics sit closer together. What LLY's price implies is a demanding bet versus history and the cohort (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | AZN | LLY |
|---|---|---|
| Price | $169.00 | $1196.14 |
| Market cap | $261.9B | $1.07T |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +26.7% |
| P/E | 25.6 | 42.5 |
| P/B | 5.38 | 34.35 |
| P/S | 4.46 | 14.83 |
| EV/EBITDA | 18.6 | 2180.2 |
| Revenue growth | +12.1% | +47.4% |
| Gross margin | 81.9% | — |
| Operating margin | 23.4% | — |
| Net margin | 17.4% | 35.0% |
| Return on equity | 21.0% | 81.0% |
| Return on assets | 9.0% | 21.7% |
| Return on invested capital | 23.3% | — |
| FCF yield | 4.5% | 1.9% |
| Dividend yield | — | 0.5% |
| Debt / equity | 0.00 | 1.39 |
| Current ratio | 0.94 | 1.50 |
| Altman Z (solvency) | 3.43 | 7.16 |
| Piotroski F (quality) | 8 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.